Scarica l'app Stockscreener
3.90
0.26%
-0.00
Precedente Chiudi:
$3.90
Aprire:
$3.84
Volume 24 ore:
1,522
Relative Volume:
0.07
Capitalizzazione di mercato:
$10.73M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+14.05%
1M Prestazione:
+6.28%
6M Prestazione:
+35.54%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$3.76
$3.84
Intervallo di 1 settimana:
$3.37
$3.90
Portata 52W:
$1.96
$6.60
Cosciens Biopharma Inc Stock (CSCI) Company Profile
Nome
Cosciens Biopharma Inc
Settore
Industria
Telefono
-
Indirizzo
-
Confronta CSCI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CSCI
Cosciens Biopharma Inc
|
3.80 | 10.73M | 0 | 0 | 0 | 0.00 |
|
ONC
Beone Medicines Ltd Adr
|
261.57 | 26.01B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.73 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.365 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
85.51 | 6.29B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
496.68 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Cosciens Biopharma Inc Borsa (CSCI) Ultime notizie
COSCIENS Biopharma reconstitutes board - MSN
COSCIENS BiopharmaEnters Resolution Agreement With Goodwood, Goodwood Fund, And Puccetti Funds Management - marketscreener.com
COSCIENS Biopharma Schedules Virtual Annual Meeting for June 30, 2025 - TipRanks
COSCIENS Biopharma Inc. Reconstitutes Board for Benefit of Share - GuruFocus
Cosciens Biopharma Brief: Entering Into a Resolution Agreement With Goodwood Inc. As Co Reconstitutes Board for Benefit of Shareholders - marketscreener.com
COSCIENS Biopharma Inc. Reconstitutes Board for Benefit of Shareholders - Yahoo Finance
Cosciens Biopharma announces receipt of Goodwood intended director nominations - Yahoo Finance
COSCIENS Biopharma Receives Director Nominations Ahead of Shareholder Meeting - TipRanks
COSCIENS Biopharma Inc. Acknowledges Receipt of Intended Directo - GuruFocus
COSCIENS Biopharma Receives Director Nominations from Goodwood - TipRanks
COSCIENS Biopharma Inc. Acknowledges Director Nominations from Goodwood Fund Ahead of Annual Shareholder Meeting - Nasdaq
COSCIENS Biopharma Inc. Acknowledges Receipt of Intended Director Nominations from Goodwood for the Upcoming Annual and Special Meeting of Shareholders - The Manila Times
Cosciens Biopharma Brief: Acknowledging Receipt of Intended Director Nominations from Goodwood for the Upcoming Annual and Special Meeting of Shareholders - marketscreener.com
Goodwood Seeks Board Overhaul At Cosciens Biopharma - Finimize
Goodwood to Nominate New Directors for COSCIENS Biopharma Inc. - The Globe and Mail
Goodwood To Nominate New Directors For COSCIENS Biopharma Inc. - Barchart.com
Databricks Announces 2025 Data + AI Summit Keynote Lineup and Data Intelligence Programming - The Globe and Mail
COSCIENS Biopharma Reports Q1 2025 Results and Updates - TipRanks
COSCIENS Biopharma reports key corporate updates By Investing.com - Investing.com India
COSCIENS Biopharma reports key corporate updates - Investing.com
COSCIENS Biopharma Completes Merger with Ceapro and Restructures Governance - TipRanks
Waverley Pharma: Top 10 Undervalued Biotechnology Industry Stocks (WAVE) - The Globe and Mail
COSCIENS Biopharma: Q1 Earnings Snapshot - CT Insider
COSCIENS Biopharma reports Q1 2025 results, updates strategy By Investing.com - Investing.com Nigeria
COSCIENS Biopharma Inc. Reports First Quarter 2025 Financial Res - GuruFocus
COSCIENS Biopharma reports Q1 2025 results, updates strategy - Investing.com
COSCIENS Biopharma Reports Q1 2025 Results and Strategic Updates - TipRanks
COSCIENS Biopharma Reports Q1 2025 Financial Results Amid Strategic Shifts - TipRanks
Cosciens Biopharma Brief: Appointing Global Consumer Products and Biosciences Executive, Anna Biehn as Chief Executive Officer - marketscreener.com
Cosciens Biopharma Brief: Company Says Ended Quarter with US$13.8 Million in Cash - marketscreener.com
Cosciens Biopharma Brief: Reported a Q1 Consolidated Net Loss of US$3.7 Million, or $1.16 Loss Per Common Share - marketscreener.com
COSCIENS Biopharma Inc. Transitions to Pure-Play Natural Products Company, Announces Phase 2 Clinical Trial Advancements and New CEO Appointment - Nasdaq
COSCIENS Biopharma Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update - Yahoo Finance
COSCIENS Biopharma Inc. Reports Transformative Year - TipRanks
COSCIENS Biopharma Sets Date for Annual Meeting Amid Strategic Shifts - TipRanks
Fennec Pharmaceuticals: Top 10 Undervalued Biotechnology Industry Stocks (FRX) - The Globe and Mail
Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last Week - MSN
COSCIENS Biopharma appoints Anna Biehn as new CEO amid leadership change - N24.com.tr
COSCIENS Biopharma Inc. Appoints Global Consumer Products and Bi - GuruFocus
COSCIENS Biopharma (CSCI) Names Anna Biehn as New CEO | CSCI Sto - GuruFocus
COSCIENS Biopharma names new CEO Anna Biehn By Investing.com - Investing.com Canada
COSCIENS Biopharma names new CEO Anna Biehn - Investing.com Australia
COSCIENS Biopharma names Anna Biehn as new CEO By Investing.com - Investing.com South Africa
COSCIENS Biopharma Full Year 2024 Earnings: US$5.93 loss per share (vs US$1.89 loss in FY 2023) - simplywall.st
COSCIENS Biopharma names Anna Biehn as new CEO - Investing.com Australia
Cosciens Biopharma appoints Biehn as CEO - TipRanks
COSCIENS Biopharma Appoints Anna Biehn as New CEO to Drive Growth in Natural-Based Products - TipRanks
Cosciens Biopharma Inc Azioni (CSCI) Dati Finanziari
Non sono disponibili dati finanziari per Cosciens Biopharma Inc (CSCI). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.87%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):